Back to News
Market Impact: 0.3
GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications
Source: thenewswire.com
Healthcare & BiotechCompany Fundamentals
The oral GLP-1 market is projected to grow from $5.1 billion in 2026 to $89 billion in 2034. Novo announced additional weight loss among patients switching from injected to oral delivery; the headline provides no magnitude or study details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
NVO0.55
More News
- Weight-loss drugs show signs of slowing biological aging, say drugmakers
- Why Dangote’s Nigeria Refinery IPO Is Such a Big Deal for Africa
- A 32% beat, a +6% jump: the IT solutions name our models picked in July
- Nvidia Is on the Verge of a $6 Trillion Market Value
- Controversial $110 billion mega-merger of Paramount and Warner Bros. finally closes
- What Marvell's rosy long-term guidance means for our AI chip stocks